Vancomycin intermittent dosing interval — Competitive Intelligence Brief

Vancomycin intermittent dosing interval (Vancomycin intermittent dosing interval) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycopeptide antibiotic. Area: Infectious Disease.

marketed Glycopeptide antibiotic Bacterial peptidoglycan (D-Ala-D-Ala) Infectious Disease Small molecule

Target snapshot

Vancomycin intermittent dosing interval (Vancomycin intermittent dosing interval) — Massachusetts General Hospital. Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vancomycin intermittent dosing interval TARGET	Vancomycin intermittent dosing interval	Massachusetts General Hospital	marketed	Glycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
Prophylactic Vancomycin	Prophylactic Vancomycin	Memorial Sloan Kettering Cancer Center	phase 3	Glycopeptide antibiotic	Bacterial peptidoglycan D-Ala-D-Ala precursors
Aerosolized Tobramycin or Vancomycin	Aerosolized Tobramycin or Vancomycin	Wright State University	marketed	Aminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin)	Bacterial 30S ribosomal subunit (tobramycin) / Bacterial cell wall peptidoglycan (vancomycin)
Vancomycin (POC)	Vancomycin (POC)	University of Maryland, Baltimore	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Administration of Vancomycin	Administration of Vancomycin	University of Colorado, Denver	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Vancomycin CI	Vancomycin CI	Wake Forest University Health Sciences	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Teicoplanin antimicrobial-lock solution	Teicoplanin antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Glycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycopeptide antibiotic class)

1. Clinica Universidad de Navarra, Universidad de Navarra · 2 drugs in this class
2. Memorial Sloan Kettering Cancer Center · 2 drugs in this class
3. Wake Forest University Health Sciences · 2 drugs in this class
4. VA Office of Research and Development · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Murdoch Childrens Research Institute · 1 drug in this class
7. OrthoCarolina Research Institute, Inc. · 1 drug in this class
8. University of Colorado, Denver · 1 drug in this class
9. University of Maryland, Baltimore · 1 drug in this class
10. Debiopharm International SA · 1 drug in this class